Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation

Dalia A Gaber1,2 1Department of Quality Control & Quality Assurance, Holding Company for Biological Products and Vaccines, Cairo, Egypt; 2Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah, Saudi ArabiaCorrespondence: Dalia A Gaber Tel +20 1013379892Fax +20 2 22415...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Gaber DA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	hyperlipidemia hpmc nano size factors antisolvent bioavailability Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f50d5d3afc934004bfff550ac888260d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f50d5d3afc934004bfff550ac888260d
record_format	dspace
spelling	oai:doaj.org-article:f50d5d3afc934004bfff550ac888260d2021-12-02T10:06:28ZNanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation1178-2013https://doaj.org/article/f50d5d3afc934004bfff550ac888260d2020-06-01T00:00:00Zhttps://www.dovepress.com/nanoparticles-of-lovastatin-design-optimization-and-in-vivo-evaluation-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Dalia A Gaber1,2 1Department of Quality Control & Quality Assurance, Holding Company for Biological Products and Vaccines, Cairo, Egypt; 2Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah, Saudi ArabiaCorrespondence: Dalia A Gaber Tel +20 1013379892Fax +20 2 224154781Email dr_daliaahmed@hotmail.comIntroduction: The aim of the study was to optimize the processing factors of precipitation–ultrasonication technique to prepare nano-sized particles of Lovastatin (LA) for enhancing its solubility, dissolution rate and in vivo bioavailability.Methods: LA nanoparticles (LANs) were prepared using precipitation–ultrasonication technique under different processing factors. LANs were characterized in terms of particle size, zeta potential and in vitro release. Stability studies at 4°C, 25°C and 40°C were conducted for optimum formulation. In addition, the in vivo bioavailability of the optimum formula was studied in comparison to a marketed product in white master rats.Results: The optimized LAN formula (LAN15) had particle size (190± 15), polydispersity index (0.626± 0.11) and a zeta potential (− 25± 1.9 mV). The dissolution study of the nanosuspensions showed significant enhancement compared with pure drug. After 50 min, only 20.12± 1.85% of LA was dissolved while 99.1± 1.09% of LA was released from LAN15. Stability studies verified that nanosuspensions at 4°C and 25°C showed higher stability with no particle growth compared to the samples studied at 40°C. In vivo studies conducted in rats verified that there was 1.45-fold enhancement of Cmax of LAN15 as compared to marketed tablets.Conclusion: Nanoparticle prepared by ultrasonication-assisted precipitation method is a promising formula for enhancing the solubility and hence the bioavailability of Lovastatin.Keywords: hyperlipidemia, HPMC, nano size, factors, antisolvent, bioavailabilityGaber DADove Medical Pressarticlehyperlipidemiahpmcnano sizefactorsantisolventbioavailabilityMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 4225-4236 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	hyperlipidemia hpmc nano size factors antisolvent bioavailability Medicine (General) R5-920
spellingShingle	hyperlipidemia hpmc nano size factors antisolvent bioavailability Medicine (General) R5-920 Gaber DA Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation
description	Dalia A Gaber1,2 1Department of Quality Control & Quality Assurance, Holding Company for Biological Products and Vaccines, Cairo, Egypt; 2Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah, Saudi ArabiaCorrespondence: Dalia A Gaber Tel +20 1013379892Fax +20 2 224154781Email dr_daliaahmed@hotmail.comIntroduction: The aim of the study was to optimize the processing factors of precipitation–ultrasonication technique to prepare nano-sized particles of Lovastatin (LA) for enhancing its solubility, dissolution rate and in vivo bioavailability.Methods: LA nanoparticles (LANs) were prepared using precipitation–ultrasonication technique under different processing factors. LANs were characterized in terms of particle size, zeta potential and in vitro release. Stability studies at 4°C, 25°C and 40°C were conducted for optimum formulation. In addition, the in vivo bioavailability of the optimum formula was studied in comparison to a marketed product in white master rats.Results: The optimized LAN formula (LAN15) had particle size (190± 15), polydispersity index (0.626± 0.11) and a zeta potential (− 25± 1.9 mV). The dissolution study of the nanosuspensions showed significant enhancement compared with pure drug. After 50 min, only 20.12± 1.85% of LA was dissolved while 99.1± 1.09% of LA was released from LAN15. Stability studies verified that nanosuspensions at 4°C and 25°C showed higher stability with no particle growth compared to the samples studied at 40°C. In vivo studies conducted in rats verified that there was 1.45-fold enhancement of Cmax of LAN15 as compared to marketed tablets.Conclusion: Nanoparticle prepared by ultrasonication-assisted precipitation method is a promising formula for enhancing the solubility and hence the bioavailability of Lovastatin.Keywords: hyperlipidemia, HPMC, nano size, factors, antisolvent, bioavailability
format	article
author	Gaber DA
author_facet	Gaber DA
author_sort	Gaber DA
title	Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation
title_short	Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation
title_full	Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation
title_fullStr	Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation
title_full_unstemmed	Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation
title_sort	nanoparticles of lovastatin: design, optimization and in vivo evaluation
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f50d5d3afc934004bfff550ac888260d
work_keys_str_mv	AT gaberda nanoparticlesoflovastatindesignoptimizationandinvivoevaluation
_version_	1718397681813946368

Nanoparticles of Lovastatin: Design, Optimization and in vivo Evaluation

Ejemplares similares